StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Thursday. The brokerage issued a sell rating on the medical technology company’s stock.

A number of other brokerages have also commented on BIOL. Benchmark reaffirmed a “speculative buy” rating and set a $0.40 price objective on shares of BIOLASE in a research report on Wednesday, October 2nd. Ascendiant Capital Markets cut their price target on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.

BIOLASE Price Performance

NASDAQ:BIOL opened at $0.01 on Thursday. BIOLASE has a one year low of $0.02 and a one year high of $1.94. The company has a fifty day moving average price of $0.02 and a 200 day moving average price of $0.07. The stock has a market cap of $213,804.80, a P/E ratio of 0.00 and a beta of 0.67.

Hedge Funds Weigh In On BIOLASE

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC boosted its holdings in BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the quarter. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 at the end of the most recent quarter. 8.79% of the stock is currently owned by institutional investors.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.